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Abstract
Background: Effective inhibition of plasma kallikrein may have significant benefits
for patients with hereditary angioedema due to deficiency of C1 inhibitor (C1-INHHAE) by reducing the frequency of angioedema attacks. Avoralstat is a small molecule inhibitor of plasma kallikrein. This study (OPuS-2) evaluated the efficacy and
safety of prophylactic avoralstat 300 or 500 mg compared with placebo.
Methods: OPuS-2 was a Phase 3, multicenter, randomized, double-blind, placebocontrolled, parallel-group study. Subjects were administered avoralstat 300 mg, avoralstat 500 mg, or placebo orally 3 times per day for 12 weeks. The primary efficacy
endpoint was the angioedema attack rate based on adjudicator-confirmed attacks.
Results: A total of 110 subjects were randomized and dosed. The least squares (LS)
mean attack rates per week were 0.589, 0.675, and 0.593 for subjects receiving
avoralstat 500 mg, avoralstat 300 mg, and placebo, respectively. Overall, 1 subject
in each of the avoralstat groups and no subjects in the placebo group were attackfree during the 84-day treatment period. The LS mean duration of all confirmed
attacks was 25.4, 29.4, and 31.4 hours for the avoralstat 500 mg, avoralstat
300 mg, and placebo groups, respectively. Using the Angioedema Quality of Life
Questionnaire (AE-QoL), improved QoL was observed for the avoralstat 500 mg
group compared with placebo. Avoralstat was generally safe and well tolerated.
Conclusions: Although this study did not demonstrate efficacy of avoralstat in preventing angioedema attacks in C1-INH-HAE, it provided evidence of shortened
angioedema episodes and improved QoL in the avoralstat 500 mg treatment group
compared with placebo.
KEYWORDS

C1 inhibitor, hereditary angioedema, oral kallikrein inhibitor, prophylaxis

1 | BACKGROUND

role of BK as the principal mediator of the signs and symptoms of
C1-INH-HAE.3-5 Activation of the BK B2 receptor by BK results in vasodi-

Hereditary angioedema (HAE) with C1 inhibitor deficiency (C1-INH-

latation, increased vascular permeability, and smooth muscle contraction,

HAE) is an autosomal dominant disorder characterized by recurrent

all of which contribute to the angioedema attacks in C1-INH-HAE

episodes of swelling of the skin, pharynx, larynx, gastrointestinal tract,

patients.3 Oropharyngeal and laryngeal swelling can be life-threatening.

genitals, and extremities,1 and is due primarily to mutations in the SERP-

Angioedema attacks in other sites, including the limbs, genitalia, face, and

ING1 gene that results in insufficient production of the natural plasma

intestines, can be painful, disabling, and disfiguring, and have a significant

kallikrein inhibitor, C1 inhibitor (C1-INH). C1-INH is a serine protease

impact on functionality and quality of life of the patients.6-9

inhibitor (serpin) that prevents uncontrolled contact activation and

The effective management of C1-INH-HAE involves the preven-

bradykinin (BK) production by covalently binding to and inactivating

tion and treatment of angioedema attacks.10 Kallikrein is a proven tar-

kallikrein, a serine protease integral to the contact activation pathway.2

get in the treatment of C1-INH-HAE. In the EU and the United States,

Extensive evidence from animal models and clinical studies supports the

licensed therapy for long-term or routine prevention of angioedema
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attacks is limited to purified plasma-derived C1-INH administered

level (Type I HAE) or a normal C1-INH antigenic level and a low C1

intravenously (Cinryzeâ) or subcutaneously (Haegardaâ – USA only)

INH functional level (Type II HAE) were eligible. Documentation of

every 3-4 days; oral doses of attenuated androgens (such as danazol)

minimum angioedema attack rate of 2 per month was required,

are also prescribed for C1-INH-HAE attack prophylaxis. While admin-

either by audit of medical record (at least 2 angioedema attacks per

istration of androgens is convenient, unacceptable adverse effects

month for 3 consecutive months within the 6 months prior to

(such as androgenic hormonal effects, intracranial hypertension, and

screening) or a subject diary record of at least 4 unique angioedema

hepatocellular adenoma and carcinoma) and contraindications (includ-

attacks collected in a run-in period of a maximum of 2 months, with

ing pregnancy and pediatrics) limit their clinical use.

10,11

at least 1 attack occurring each month. Use of C1INH or tranexamic

Avoralstat (formerly BCX4161) is a potent, small molecule inhibitor

acid within 7 days prior to the screening visit or expected use at any

of kallikrein that was discovered at BioCryst Pharmaceuticals, Inc.12

time during the study was exclusionary. The use of androgens within

Effective inhibition of kallikrein with an orally bioavailable small mole-

30 days was also an exclusion criterion unless the subject was

cule such as avoralstat may have significant benefits for patients with

receiving a stable dose of androgens at least 90 days prior to the

C1-INH-HAE by reducing the frequency of angioedema attacks. In a

screening visit, met the required angioedema attack frequency while

prior Phase 2 study, the safety and efficacy of avoralstat 400 mg taken

on the stable dose, and planned to remain on the current dose of

3 times per day were evaluated as a prophylactic treatment to reduce

androgens during the study.

the frequency of angioedema attacks in subjects with C1-INH-HAE.

13

Treatment with avoralstat resulted in significantly fewer angioedema
attacks per week, demonstrating proof of concept for avoralstat in the

2.3 | Study treatment

prevention of angioedema attacks in subjects with C1-INH-HAE. In the

Subjects received avoralstat 500 mg, avoralstat 300 mg, or placebo

Phase 2 study, treatment with avoralstat also showed statistically sig-

administered orally 3 times per day for 12 weeks, and were asked to

nificant improvements in subject quality of life (QoL), severity of dis-

avoid taking study drug with food. Study drug assignment was

ease, and number of attack-free days. Avoralstat was generally well

blinded to the investigator and clinical site personnel, study subjects,

tolerated with no discontinuations due to drug-related adverse events

and study staff.

(AEs), no Grade 4 AEs or treatment-related serious adverse events
(SAEs), and few Grade 3 AEs or laboratory abnormalities.
This OPuS-2 Phase 3 study evaluated the efficacy and safety of

2.4 | Study measures

prophylactic avoralstat 300 and 500 mg administered 3 times per day

The primary efficacy outcome was weekly angioedema attack rate

for 12 weeks compared with placebo, assessed the effects of avoral-

based on the number of confirmed episodes. Secondary efficacy

stat on C1-INH-HAE disease activity and angioedema attack charac-

endpoints included the weekly subject-reported attack rate, number

teristics. This study also evaluated the effects of avoralstat on patients’

of attack-free days, the AE-QoL score, and the average attack sever-

QoL and described the population pharmacokinetics (PK) of avoralstat.

ity score. Efficacy data collected included the number of angioedema
attacks and related details (timing, severity, duration of symptoms,

2 | METHODS
2.1 | Study design

anatomical location, treatment used [if any]), number of attack-free
days, Angioedema Quality of Life (AE-QoL) Questionnaire,14,15 and
angioedema activity score (AAS,16). An angioedema attack was
defined as subject-reported indication of swelling at any location fol-

OPuS-2 was a Phase 3, multicenter, randomized, double-blind, pla-

lowing a report of no swelling on the previous day. Abdominal

cebo-controlled, parallel-group study performed at 46 centers in North

attacks were defined by abdominal pain with or without nausea or

America and Europe. Eligible subjects, stratified by screening angioe-

vomiting; laryngeal attacks were defined by difficulty swallowing or

dema attack rates (≥1 attack per week vs <1 attack per week), were

breathing, voice change, or lump or tightness in the throat. Periph-

randomized in a 1:1:1 ratio to receive avoralstat 500 mg, avoralstat

eral attacks were defined by cutaneous swelling. Prior to inclusion in

300 mg, or placebo administered orally 3 times per day for 12 weeks.

efficacy analyses, each subject-reported angioedema attack was

Details of HAE attacks were recorded in an electronic diary. Attacks

reviewed by the investigator, and all attacks were reviewed and con-

were treated in accordance with the subject’s normal standard of care.

firmed or rejected by an expert adjudication panel blinded to treat-

The OPuS-2 trial (www.clinicaltrials.gov ID# NCT02303626 and

ment arm.

EudraCT # 2014-002655-26) was approved by independent ethics

Plasma samples for determination of avoralstat concentrations

committees or institutional review boards. All patients provided writ-

were collected at baseline (Day 1) and predose (trough) at the Week

ten informed consent.

4, 8, and 12 visits for all subjects. Subjects who consented to participate in a PK substudy had additional plasma samples drawn through

2.2 | Subjects

6 hours following the first dose on Day 1 and for one morning dose
at or between the Week 4 and Week 8 visits.

Subjects aged ≥18 years of age with a clinical diagnosis of type 1 or

Safety was assessed by monitoring of adverse events (AEs) and

2 C1-INH-HAE as documented by either a low C1 INH antigenic

through clinical laboratory assessments, vital signs, electrocardiograms
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(ECGs), abdominal ultrasonography, and physical examinations. An

baseline in AE-QoL data were summarized by the four AE-QoL

independent data monitoring committee periodically reviewed safety

domain scores and a total score using the appropriate scoring algo-

data.

rithm. Average attack severity score was summarized.
Avoralstat plasma PK parameters were estimated using noncompartmental analysis (Phoenix WinNonlin, version 6.4 or later).

2.5 | Populations for analysis

Safety data were summarized descriptively.

The intent-to-treat (ITT) and safety populations included all subjects
who were randomized and received at least 1 dose of study drug.

3 | RESULTS

2.6 | Statistical analysis

3.1 | Baseline characteristics

The primary efficacy endpoint was the angioedema attack rate based

The study was conducted from December 2014 to January 2016.

on confirmed attacks. The study was designed to investigate the

Of the 137 subjects screened, 110 subjects were randomized and

superiority of avoralstat over placebo. Assuming a normalized placebo

dosed (Figure 1). Of the 110 subjects randomized, 103 subjects

attack rate of 1 unit and standard deviations of 0.45 and 0.40 units

(93.6%) completed study drug and 7 subjects (6.4%) discontinued

for avoralstat and placebo attack rates, respectively, a sample size of

study drug prior to Week 12. Reasons for study drug discontinuation

32 subjects was anticipated to have 90% power to detect a treat-

included AEs (1 subject due to rash and 1 subject due to angioe-

ment difference of 0.35 units per time period between avoralstat and

dema attack in the avoralstat 500 mg group), lack of efficacy (1 sub-

placebo, based on a 2-sided test at a significance level of 0.05.

ject each in the avoralstat 300 mg group and the placebo group), a

An analysis of covariance (ANCOVA) model, including treatment

positive pregnancy test (1 subject in the placebo group), protocol

group as a fixed term and angioedema attack stratum (≥1 or <1 at-

violation (1 subject in the avoralstat 500 mg group), and study non-

tack per week) as a covariate, was used for the primary analysis,

compliance (1 subject in the placebo group).

which reported the estimated treatment difference in attack rate (for

The majority of subjects were female (77.3%) and Caucasian

each avoralstat dose minus placebo) with its associated 95% CI and

(92.7%), the mean age was 41.2 years, and the mean BMI was

P-value.

26.8 kg/m2 (Table 1). A small number of subjects (9.1%) continued

Secondary efficacy endpoints included the number of attack-free

with concurrent androgen prophylaxis on study. The mean (SD)

days, the AE-QoL score, the number of subject-reported attacks, and

weekly qualifying attack rate was 0.93 (0.37). Baseline demographics

the average attack severity score. Attack-free days were analyzed in

and disease characteristics were generally similar across the treat-

a similar manner as the primary efficacy endpoint. Changes from

ment groups.

Screened
n = 137

Excluded n = 27
Failed inclusion/exclusion
Consent withdrawn
Lost to follow-up
Investigator discretion

Randomized
n = 110

BCX4161 500 mg TID n = 38
Dosed
n = 38
ITT
n =38
Safety
n = 38

BCX4161 300 mg TID n = 36
Dosed
n = 36
ITT
n = 36
Safety
n = 36

Placebo
Dosed
ITT
Safety

n = 36
n = 36
n = 36
n = 36

Discontinued drug
n=3
AE
n=2
Protocol violation n = 1

Discontinued drug
n=1
Lack of efficacy n = 1

Discontinued drug
Lack of efficacy
Non-compliance
Withdrew consent

n=3
n=1
n=1
n=1

Discontinued study
Protocol violation
Withdrew consent
FIGURE 1

n=3
n=1
n=2

Discontinued study
Withdrew consent

n=1
n=2

n = 20
n=4
n=2
n=1

Discontinued study n = 3
Non-compliance n = 1
Withdrew consent n = 2

Consort diagram. AE, adverse event; ITT, intent to treat; TID, 3 times per day
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T A B L E 1 Demographics and select baseline disease characteristics (ITT population)

Age (years), mean (SD)
Sex (female), n (%)
Baseline BMI (kg/m2), mean (SD)

Avoralstat 500 mg
TID (N = 38)

Avoralstat 300 mg
TID (N = 36)

Placebo
(N = 36)

Total
(N = 110)

41.1 (15.1)

40.4 (12.4)

42.1 (12.5)

41.2 (13.3)

30 (78.9)
26.7 (4.5)

29 (80.6)
28.1 (5.4)

26 (72.2)
25.6 (3.9)

85 (77.3)
26.8 (4.7)

Race, n (%)
American Indian or Alaska Native

0

1 (2.8)

0

1 (0.9)

Asian

1 (2.6)

1 (2.8)

0

2 (1.8)

Native Hawaiian or Other Pacific Islander

1 (2.8)

1 (2.8)

2 (1.8)

White

36 (94.7)

0

32 (88.9)

34 (94.4)

102 (92.7)

Other

1 (2.6)

1 (2.8)

1 (2.8)

3 (2.7)

Type I

34 (89.5)

32 (88.9)

35 (97.2)

101 (91.8)

Type II

4 (10.5)

4 (11.1)

1 (2.8)

9 (8.2)

Hereditary angioedema type, n (%)

Age at diagnosis of C1-INH-HAE (years), mean (SD)

17.8 (10.6)

19.4 (12.1)

22.8 (12.1)

20.0 (11.7)

Qualifying attack rate (attack/week)a, mean (SD)

0.95 (0.39)

0.93 (0.39)

0.92 (0.34)

0.93 (0.37)

<1 attack per week, n (%)

26 (68.4)

26 (72.2)

22 (61.1)

74 (67.3)

≥1 attack per week, n (%)

12 (31.6)

10 (27.8)

14 (38.9)

36 (32.7)

2 (5.3)

4 (11.1)

4 (11.1)

10 (9.1)

Concurrent androgen use, n (%)

BMI, body mass index; C1-INH-HAE, hereditary angioedema due to C1 inhibitor deficiency; ITT, intent to treat; SD, standard deviation; TID, 3 times
per day.
a
Qualifying HAE attack rate was derived based on subject-reported historical attacks or attacks during the run-in period when historical attack data
were not available.

3.2 | Primary efficacy measure

greater than in the placebo group at Week 4 ( 7.23 points,
P = .03) and Week 8 ( 8.83 points, P = .01), but not at Week 12

The least squares (LS) mean attack rates per week of confirmed

( 5.31 points, P = .16) (Table 3). Greater reductions were observed

attacks were 0.59, 0.68, and 0.59 for subjects during treatment with

for the avoralstat 500 mg group compared with placebo for each of

avoralstat 500 mg, avoralstat 300 mg, and placebo groups, respec-

the individual domain scores with significant differences observed

tively (P ≥ .5, Table 2).

at specific time points: Weeks 4 and 8 for functioning, Week 8 for
fear/shame, and Week 12 for fatigue/mood. No significant differ-

3.3 | Secondary efficacy measures
The LS mean attack rates per week of all subject-reported attacks
were 0.62, 0.73, and 0.65 for subjects in the avoralstat 500 mg, avo-

ences were observed between the avoralstat 300 mg group and
placebo at any time point.
Angioedema activity score scores were not significantly different
comparing either 500 mg or 300 avoralstat groups with placebo.

ralstat 300 mg, and placebo groups, respectively (P ≥ .5, Table 2).
The LS mean attack rates per week of confirmed attacks requiring
treatment were 0.49, 0.58, and 0.50 for subjects in the avoralstat

3.4 | Pharmacokinetics

500 mg, avoralstat 300 mg, and placebo groups, respectively

Following multiple oral dose administration, maximal avoralstat con-

(Table 2). The most commonly used medications to treat attacks

centrations were achieved approximately 1 hour postdose. Plasma

were icatibant and plasma-derived C1-INH concentrate.

concentrations are shown in Figure 2. A large variability in plasma

Both the number and percent of attack-free days were similar

concentrations was observed at both doses, with many time points

between active and placebo treatment groups, with approximately

below the target therapeutic concentration of 4-8 times the EC50 of

80% of the total days on study treatment attack-free. Overall, 1 sub-

avoralstat for plasma kallikrein.

ject in each of the avoralstat groups and no subjects in the placebo
group were attack-free during the 84-day treatment period. The LS
mean duration of all confirmed attacks was 25.4, 29.4, and

3.5 | Safety

31.4 hours for subjects in the avoralstat 500 mg (P = .01), avoralstat

Avoralstat was generally safe and well tolerated, with only 2 dis-

300 mg (P = .40), and placebo groups, respectively.

continuations due to unrelated AEs (an angioedema attack, consid-

The LS mean reduction from baseline (improvement) in total

ered serious, and a mild rash; both in the avoralstat 500 mg group),

AE-QoL scores in the avoralstat 500 mg group was significantly

and no life-threatening AEs or treatment-related SAEs were
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T A B L E 2 Summary of primary and secondary efficacy endpoints (ITT population)
Avoralstat 500 mg
TID (N = 38)

Avoralstat 300 mg
TID (N = 36)

Placebo
(N = 36)

Weekly rate of confirmed attacks
LS mean

0.59

0.68

Differencea (95% CI)

0.00 ( 0.25, 0.24)

0.08 ( 0.17, 0.33)

Treatment effect P-value

.98

.51

0.62

0.73

0.03 (0.29,0.23)

0.08 ( 0.18, 0.35)

0.59

Weekly rate of subject-reported attacks
LS mean
a

Difference (95% CI)
Treatment effect P-value

.80

.53

0.49

0.58

0.02 ( 0.27, 0.23)

0.07 ( 0.18, 0.32)

0.65

Weekly rate of confirmed attacks requiring treatment
LS mean
a

Difference (95% CI)

0.50

Attack duration hours
LS mean
Differencea (95% CI)
Treatment effect P-value

25.4

29.4

6.0

2.0

.01

31.4

.40

Number of attack-free days
LS mean

67.2
a

Difference (95% CI)
Treatment effect P-value

3.0 ( 4.5, 10.4)
.43

64.1

64.2

0.1 ( 7.7, 7.5)
.98

Attack-free subjects
n (%)

1 (2.6)

1 (2.8)

0

AAS84
LS mean
a

Difference (95% CI)
Treatment effect P-value

83.94

109.08

10.90

14.24

.59

.49

94.84

AAS, angioedema activity score; AE-QoL, angioedema quality of life; CI, confidence interval; ITT, intent to treat; LS, least squares; TID, 3 times per day.
Avoralstat – placebo.

a

reported. No deaths were reported. Most AEs were mild or moder-

4 | DISCUSSION

ate in severity. Grade 3 AEs considered related to study drug were
flatulence, diarrhea, and abdominal distension in the avoralstat

This study failed to confirm the benefit of avoralstat in reducing

300 mg group and flatulence and headache in the placebo group.

angioedema attack rates seen in the OPuS-1 Phase 2 study. With

No Grade 3 AEs considered related to study drug were reported in

the exception of quality of life, no differences were observed in the

the 500 mg group. No treatment-emergent Grade 4 AEs were

prespecified secondary endpoints of the study, although the LS

reported.

mean attack duration for the avoralstat 500 mg group was signifi-

The most commonly reported AEs (Table 4) in the combined

cantly less than placebo.

avoralstat groups and placebo, respectively, were diarrhea (32.4%,

The failure of this Phase 3 study was surprising, given the clear

33.3%), flatulence (20.3%, 25.0%), and nasopharyngitis (17.6%,

treatment effect demonstrated in the earlier Phase 2 study, OPuS-1.

19.4%). The nature and frequency of the AEs were generally simi-

A number of factors associated with the PK of avoralstat may

lar between the avoralstat treatment groups and the placebo

explain the poor outcome observed in this study.

group.

Overall, reported study drug compliance was high with a

Grade 3 or 4 chemistry abnormalities generally occurred in a

median compliance rate of approximately 99% across all treat-

similar proportion of subjects in the avoralstat and placebo groups.

ment groups. However, trough PK data indicate a wide spread

No subject experienced a Grade 3 or 4 hematology or coagulation

in the time since last recorded dose of study drug, indicating

laboratory abnormality. No notable changes in vital signs (systolic

that adherence to an 8-hourly dosing regimen and taking study

and diastolic blood pressure and pulse) were reported during the

drug on an empty stomach, which were required due to the

study.

short plasma half-life of the drug and known food effect on
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T A B L E 3 Summary of the LS mean change from baseline in the total AE-QoL score (ITT population)
Treatment

N

LS mean

Standard
error

P-value for
treatment difference

95% CI for
treatment difference

Difference
vs placeboa

Week 4
Avoralstat 500 mg

38

16.63

2.37

7.23

Avoralstat 300 mg

35

5.06

2.47

4.34

Placebo

33

9.41

2.14

37

18.55

2.66

Avoralstat 300 mg

34

10.96

3.02

Placebo

33

9.72

2.08

36

17.45

2.66

13.6,

0.8

.03

2.2, 10.9

—

.19

—

—

Week 8
Avoralstat 500 mg

8.83

15.6,

1.23

2.1

.01

8.6, 6.1

—

.74

—

—

Week 12
Avoralstat 500 mg
Avoralstat 300 mg

33

9.89

3.11

Placebo

33

12.14

2.64

5.31

12.8, 2.2

2.25

.16

5.9, 10.4

—

.59

—

—

AE-QoL, angioedema quality of life; CI, confidence interval; ITT, intent to treat; LS, least squares.
a
A reduction in total score represents an improvement in QoL.

1000

exposure, respectively, was a challenge for study subjects.
Intervals between the 3 daily doses were not evenly spaced,
with the largest mean interval of approximately 11 hours.
frequency (three times daily) and food effect likely impacted
efficacy

outcomes

by

contributing

to

variability

in

drug

exposure.
Plasma concentrations of avoralstat were widely distributed,
with many time points showing drug levels below the target therapeutic range of 4-8 times the EC50 of avoralstat for plasma kallikrein. This variability in exposure was likely due to a combination
of the low oral bioavailability of the drug and its relatively rapid
17

clearance,

Avoralstat concentration, ng/mL

Thus, while reported dosing compliance was 99%, dosing
100

10

1

coupled with variation in dosing interval and food

effects.
Although there were no significant reductions in angioedema

300 mg TID, n = 53
500 mg TID, n = 57

0.1

attack rate with avoralstat compared with placebo, there was some
evidence suggesting that treatment with avoralstat 500 mg improved

0

4

quality of life. The AE-QoL scores in the avoralstat 500-mg group

8

12

16

20

Hours since last dose

showed a significant reduction (improvement) compared to placebo
at Weeks 4 and 8; however, the difference was not significant at
Week 12. QoL measures are increasingly being incorporated into
HAE treatment trials as clinically meaningful endpoints. While clearly

F I G U R E 2 Avoralstat plasma concentrations. The blue bar
represents a target therapeutic concentration in the range of 48 times the EC50 of avoralstat for plasma kallikrein in a plasmabased assay17

insufficient to prove efficacy in this study, the difference in QoL
scores between the avoralstat 500 mg group and placebo treatment

In summary, this rigorous randomized controlled trial of avoral-

groups is intriguing as a potential indirect marker of pharmacody-

stat did not demonstrate efficacy in preventing angioedema

namic effect.

attacks in C1-INH-HAE patients. However, the study provided evi-

Overall, treatment with avoralstat 500 or 300 mg 3 times daily

dence of shortened angioedema episodes and improved QoL mea-

for 12 weeks was generally safe and well tolerated with no treat-

sures in the avoralstat 500 mg treatment group compared to

ment-related SAEs. Gastrointestinal side effects were most common,

placebo, and established safety of oral kallikrein inhibition in this

but did not lead to treatment discontinuation. Gastrointestinal

study cohort.

events common to all groups were most likely due to excipients as

In the future, additional compounds of this drug class with

the rates of these events were similar in drug-treated and placebo

improved pharmacokinetic and pharmacodynamic profiles may be

groups.

of

substantial

therapeutic

benefit

in

C1-INH-HAE.

Ongoing
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T A B L E 4 Adverse events occurring in ≥5% of subjects in any treatment group (safety population)
Avoralstat 500 mg
TID (N = 38)

Avoralstat 300 mg
TID (N = 36)

Placebo
(N = 36)

Avoralstat
total (N = 74)

Number (%) of subjects with at least 1 treatment-emergent AE, n (%)
Diarrhea

16 (42.1)

8 (22.2)

12 (33.3)

24 (32.4)

Flatulence

10 (26.3)

5 (13.9)

9 (25.0)

15 (20.3)

8 (21.1)

5 (13.9)

7 (19.4)

13 (17.6)

Nasopharyngitis
Headaches

7 (18.4)

4 (11.1)

6 (16.7)

11 (14.9)

Nausea

3 (7.9)

4 (11.1)

3 (8.3)

7 (9.5)

Abdominal distension

2 (5.3)

3 (8.3)

2 (5.6)

5 (6.8)

Abdominal pain

4 (10.5)

0

2 (5.6)

4 (5.4)

Urinary tract infection

2 (5.3)

2 (5.6)

1 (2.8)

4 (5.4)

Abdominal pain upper

0

3 (8.3)

0

3 (4.1)

Blood alkaline phosphatase increased

0

3 (8.3)

0

3 (4.1)

Blood in urine present

0

3 (8.3)

0

3 (4.1)

Cystitis

2 (5.3)

1 (2.8)

0

3 (4.1)

GGT increased

0

3 (8.3)

0

3 (4.1)

Hereditary angioedema

1 (2.6)

2 (5.6)

1 (2.8)

3 (4.1)

Myalgia

1 (2.6)

2 (5.6)

0

3 (4.1)

Upper respiratory tract infection

2 (5.3)

1 (2.8)

1 (2.8)

3 (4.1)

Viral infection

2 (5.3)

1 (2.8)

0

3 (4.1)

Acne

2 (5.3)

0

1 (2.8)

2 (2.7)

Arthralgia

0

2 (5.6)

1 (2.8)

2 (2.7)

Back pain

1 (2.6)

1 (2.8)

2 (5.6)

2 (2.7)

Contusion

2 (5.3)

0

0

2 (2.7)

Dizziness

0

2 (5.6)

0

2 (2.7)

Dyspepsia

2 (5.3)

0

1 (2.8)

2 (2.7)

Feces soft

1 (2.6)

1 (2.8)

3 (8.3)

2 (2.7)

Frequent bowel movements

0

2 (5.6)

0

2 (2.7)

Gastroenteritis

1 (2.6)

1 (2.8)

2 (5.6)

2 (2.7)

Influenza

2 (5.3)

0

0

2 (2.7)

Oropharyngeal pain

0

2 (5.6)

0

2 (2.7)

Sinusitis

1 (2.6)

1 (2.8)

3 (8.3)

2 (2.7)

Tonsillitis

2 (5.3)

0

0

2 (2.7)

Vulvovaginal candidiasis

2 (5.3)

0

0

2 (2.7)

Oral herpes

0

1 (2.8)

2 (5.6)

1 (1.4)

Ovarian cyst

1 (2.6)

0

2 (5.6)

1 (1.4)

Somnolence

1 (2.6)

0

2 (5.6)

1 (1.4)

TID, 3 times per day.
Adverse events were coded using Medical Dictionary for Regulatory Activities (MedDRA) version 16.0. Treatment-emergent adverse events included
events that started on and after the date of the first dose up to the last dose plus 30 d.

studies are investigating an oral once-daily kallikrein inhibitor with
improved bioavailability and a longer half-life.
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